

NOTICE AND DISCLAIMER

This publication is intended to be a resource for physicians and other healthcare professionals who provide care and treatment to patients in resource poor settings. Reasonable efforts have been made to ensure that the material presented here is accurate, reliable, and in accord with current standards *as of the date of publication*. However, as new research and experience expand our knowledge, recommendations for care and treatment change. Your use of this publication is provided on an “as is” basis without warranty of any kind, and none of the individuals or entities listed below represent or warrant that the information contained herein is complete or accurate or free from error. It is therefore the responsibility of the individual physician or healthcare professional to use his/her best medical judgment in determining appropriate patient care or treatment.

To the maximum extent permitted under applicable laws, no responsibility is assumed by any party involved in the production or publication of this publication, including without limitation, each of the contributors and authors; Partners In Health; the Program in Infectious Disease and Social Change, Harvard Medical School; Harvard Medical School Division of AIDS; the Division of Social Medicine and Health Inequalities, Brigham and Women's Hospital; and each of their affiliates, divisions, directors, officers, trustees, agents and employees (referred to collectively as the “Publishers and Contributors”). The Publishers and Contributors hereby disclaim all liability for errors, omissions, or any injury and/or damage (actual or perceived) to persons or property as a result of any actual or alleged product liability, libelous statement, or infringement of intellectual property or privacy rights, whether resulting from negligence or otherwise, including without limitation, from any reliance upon, use or operation of, any ideas, instructions, procedures, products or methods contained in the material included in this publication.

References to specific drugs or products within this publication do not constitute endorsement by the Publishers and Contributors. Individual patient needs may vary on a case-by-case basis, and physicians and other healthcare professionals should consult their standard resources before prescribing specific drugs or products to their patients.

This disclaimer and your use of this publication are and shall be governed and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to its rules concerning conflicts of laws. In the event of any conflict between foreign laws, rules and regulations and those of the United States, the laws, rules and regulations of the United States shall govern.

By choosing to use this publication, you acknowledge and agree to the terms of this disclaimer.

Published in the United States by Partners In Health.

Subject to the rights of Partners In Health, this publication may be freely reviewed, abstracted, reproduced or translated, provided that all copyright, trademark and other proprietary notices are included in each such use.

The foregoing notwithstanding, no portion of this publication may be sold or otherwise used or distributed in conjunction with any commercial purpose.

PIH and Partners In Health are trademarks of Partners In Health, and the PIH logo is a United States registered service mark of Partners In Health. All other trademarks, service marks, trade names and logos appearing in this publication, including drug brands and names, are the property of their respective owners.

Copyright 2003 - 2004 © Partners In Health
All rights reserved under International and Pan-American Copyright Convention

Guide to the Community-Based Treatment of MDR TB

List of Appendices

General Guidelines

A1. WHO-Recommended Treatment Regimens Used in Peru's PNCT	A1
A2. Chemotherapeutic Agents Used in the Treatment of Tuberculosis	A2
A3. DOTS-Plus Organization at the Community Level	A7
A4. Guidelines on Health Worker Safety	A8
A5. Position on INH Prophylaxis in MDR TB Contacts	A9
A6. MDR TB in Pediatrics and Obstetrics	A10
A7. Guidelines for Collection and Transport of Biomaterials	A11
A8. Susceptibility Testing Methods	A13
A9. Recommendations for Treatment of HIV-TB Coinfected Patients	A14
A10. Proposed Treatment Outcome Definitions of Multidrug-resistant Tuberculosis	A15

DOTS-Plus Surveillance Protocols

P1. Nutritional Surveillance Protocol	P1
P2. Management of Positive Smear or Culture after Five or More Months of Treatment	P2

Side Effects Protocols

P3. Management of Depression	P3
P4. Management of Diarrhea	P4
P5. Management of Gastritis	P5
P6. Management of Headaches	P6
P7. Evaluation and Management of Hepatitis	P7
P8. Management of Hypothyroidism	P8
P9. Management of Nausea and Vomiting	P9
P10. Management of Nephrotoxicity	P10
P11. Management of Peripheral Neuropathy	P12

Emergency Protocols

P12. Management of Anaphylaxis and Allergic Reaction	P13
P13. Management of Psychosis	P14
P14. Management of Hypokalemia	P15
P15. Management of Seizure	P16
P16. Management of Fever	P18
P17. Management of Hemoptysis	P20
P18. Management of Respiratory Insufficiency	P22

Forms for Data Surveillance

F1. DOTS-Plus Case Registration Form	F1
F2. Checklist for Initial Evaluation and Treatment Surveillance	F6
F3. DOTS-Plus Regimen Summary Sheet	F7
F4. DOTS-Plus Smear and Culture Summary Sheet	F8
F5. DOTS-Plus Weight Surveillance Sheet	F9
F6. DOTS-Plus Susceptibility Data Summary Sheet	F10
F7. DOTS-Plus Adverse Reaction Summary Sheet	F16
F8. DOTS-Plus Treatment Administration Sheet	
F9. Evaluation at Completion of DOTS-Plus Treatment	